| Opportunity ID: |
321315 |
| Opportunity Number: |
NOT-HL-19-715 |
| Opportunity Title: |
Notice of Intent to Publish an NHLBI Funding Opportunity Announcement for STIMULATE-2 (R61/R33 – Clinical Trial Required) |
| Opportunity Category: |
Discretionary |
| Opportunity Category Explanation: |
|
| Funding Instrument Type: |
Grant |
| Category of Funding Activity: |
Health |
| Category Explanation: |
|
| CFDA Number(s): |
93.840 |
| Eligible Applicants: |
State governments
County governments
Independent school districts
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
For profit organizations other than small businesses
Small businesses
Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: |
|
| Agency Code: |
HHS-NIH11 |
| Agency Name: |
Department of Health and Human Services
National Institutes of Health |
| Posted Date: |
Oct 04, 2019 |
| Last Updated Date: |
Oct 04, 2019 |
| Estimated Synopsis Post Date: |
Dec 31, 2019 |
| Fiscal Year: |
2021 |
| Award Ceiling: |
$737,000 |
| Award Floor: |
|
| Estimated Total Program Funding: |
$3,685,000 |
| Expected Number of Awards: |
5 |
| Description: |
The NHLBI intends to publish a new milestone-driven Funding Opportunity Announcement (FOA) to invite applications for single-site, biphasic, late-stage translation (T4) research projects which will identify and test pragmatic and sustainable multi-level implementation strategies that will increase the use of evidence-based guidelines and/or proven effective interventions for preventing and/or managing heart, lung, blood diseases and/or sleep (HLBS) disorders. This anticipated FOA, Stimulating T4 Implementation Research to Optimize Integration of Proven-effective Interventions for Heart, Lung, and Blood Diseases and Sleep Disorders into Practice -2 (STIMULATE -2), is intended to complement the late-stage research portfolio for the STIMULATE-1 FOA, RFA-HL-19-014 Stimulating T4 Implementation Research to Optimize Integration of Proven-effective Interventions for Heart, Lung, and Blood Diseases and Sleep Disorders into Practice (STIMULATE) (R01 Clinical Trial Not Allowed). STIMULATE-2 applicants would address a planning phase (R61) of up to one year, and an implementation research phase (R33) of up to four years for the clinical trial. The R61 planning phase would be expected to address an approach for selecting and planning an adaptation of the evidence-based guideline or multi-level proven-effective intervention, data collection and management, a recruitment and retention plan, milestones, and a project timeline. A robust plan for the implementation research (R33) phase of the application would also be required. Upon administrative review by the NHLBI, only the meritorious R61 projects that meet the predetermined scientific milestones of the planning phase will be selected to transition to the R33 phase. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The FOA is expected to be published in winter 2020 with an expected application due date in spring 2021. This FOA will utilize the R61/R33 Clinical Trial Required activity code. Details of the planned FOA are provided below. |
| Version: |
1 |
|
